Biogen Inc.
210.73USD
-1.7700 (-0.83%)
Analyst Ratings
31 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 3 | 20 | 11 | 1 |
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2.03▼ | $3.93 | 1 | 20 |
| Next quarter | $3.27▼ | $3.68 | 4 | 17 |
| Current year | $12.61▼ | $13.34 | 4 | 19 |
| Next year | $16.54▼ | $16.59 | 11 | 12 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.03 | $3.6 | +1.57 (+77.4%) |
| 2026-03-31 | $2.95 | $3.57 | +0.62 (+20.9%) |
| 2025-12-31 | $1.62 | $1.99 | +0.37 (+23.2%) |
| 2025-09-30 | $3.88 | $4.81 | +0.93 (+23.9%) |
639 ratings from 46 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Piper Sandler | Reiterated | Overweight | $225 $245 | Sep 3, 2026 |
| RBC Capital | Maintained | Outperform | $240 $260 | Aug 25, 2026 |
| Wolfe Research | Upgraded from Peer Perform | Outperform | $300 | Aug 13, 2026 |
| Mizuho | Maintained | Outperform | $221 $241 | Aug 4, 2026 |
| Citigroup | Maintained | Neutral | $200 $215 | Aug 3, 2026 |
| UBS | Maintained | Buy | $225 $240 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $237 $251 | Jul 30, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $222 $231 | Jul 30, 2026 |
| RBC Capital | Maintained | Outperform | $242 $240 | Jul 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $245 $248 | Jul 30, 2026 |
| TD Cowen | Maintained | Buy | $215 $225 | Jul 30, 2026 |
| Wedbush | Maintained | Neutral | $201 $215 | Jul 30, 2026 |
| Barclays | Maintained | Equal-Weight | $185 $200 | Jul 29, 2026 |
| Guggenheim | Maintained | Buy | $260 $280 | Jul 21, 2026 |
| B of A Securities | Maintained | Neutral | $217 $215 | Jul 21, 2026 |
| Truist Securities | Upgraded from Hold | Buy | $190 $235 | Jul 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $224 $222 | Jul 8, 2026 |
| RBC Capital | Maintained | Outperform | $227 $242 | Jul 7, 2026 |
| Needham | Maintained | Buy | $255 $256 | Jun 29, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $206 $224 | Jun 18, 2026 |
| Mizuho | Maintained | Outperform | $236 $221 | Jun 15, 2026 |
| Needham | Upgraded from Hold | Buy | $255 | Jun 8, 2026 |
| RBC Capital | Maintained | Outperform | $222 $227 | May 27, 2026 |
| Piper Sandler | Reiterated | Overweight | $214 $225 | May 15, 2026 |
| Citigroup | Maintained | Neutral | $190 $200 | May 1, 2026 |
72 filings from 22 insiders · 12 buy / 1 sell over 6m
Officers and directors of BIIB, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Parini MichaelOfficer, Chief Legal Officer | GrantRestricted Stock Unit | 7.4k | — | — | Sep 1, 2026 |
| MINOR LLOYD B.Director | Sell | 1.2k | $200.96 | $240k | Aug 4, 2026 |
| PANGALOS MENELAS NDirector | Other | 2.4k | — | — | Jun 9, 2026 |
| ROWINSKY ERIC K.Director | Grant | 1.5k | — | — | Jun 9, 2026 |
| HAWKINS WILLIAM A IIIDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| SHERWIN STEPHEN ADirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| FREIRE MARIA CDirector | Grant | 2.0k | — | — | Jun 9, 2026 |
| MANTAS JESUS BDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| PATOLAWALA MONISH DDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| LANGER SUSANDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| PANGALOS MENELAS NDirector | Grant | 1.5k | — | — | Jun 9, 2026 |
| MINOR LLOYD B.Director | Grant | 1.5k | — | — | Jun 9, 2026 |
| KEENEY ADAM JAMESOfficer | Other | 939 | — | — | May 1, 2026 |
| GODBOUT SEANOfficer | Other | 181 | — | — | Apr 1, 2026 |
| MURPHY NICOLEOfficer | Buy | 3 | $195.04 | $585 | Feb 12, 2026 |
| SINGHAL PRIYAOfficer | Sell | 2.7k | $199.83 | $532k | Feb 9, 2026 |
| SINGHAL PRIYAOfficer | Other | 6.9k | — | — | Feb 6, 2026 |
| VIEHBACHER CHRISTOPHERChief Executive Officer | Other | 24.5k | — | — | Feb 6, 2026 |
| IZZAR RACHIDOfficer | Other | 6.9k | — | — | Feb 6, 2026 |
| GREGORY GINGEROfficer | Other | 7.2k | — | — | Feb 6, 2026 |
No analyst notes on BIIB yet.
| Buy2.29 |
| 1 mo ago | 3 | 20 | 11 | 1 | 0 | Buy2.29 |
| 2 mo ago | 3 | 20 | 12 | 1 | 0 | Buy2.31 |
| 3 mo ago | 3 | 18 | 14 | 1 | 0 | Buy2.36 |